Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
CUTANEOUS LYMPHOMA: WHERE ARE WE MOVING?
Delfino C. 1, Grandi V. 1, Pileri A. 2, Rupoli S. 3, Quaglino P. 4, Alterini R. 5, Goteri G. 6, Canafoglia L. 3, Pimpinelli N. 1
1 Division of Dermatology, Department of Critical Care Medicine and Surgery; University of Florence, Italy;
2 Division of Dermatology, Department of Internal Medicine, Geriatrics and Nephrology, University of Bologna, Bologna, Italy;
3 Division of Hematology, University of Ancona, Ancona, Italy;
4 Division of Dermatology, Department of Biomedical Sciences and Human Oncology, University of Turin, Turin, Italy;
5 Division of Hematology, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy;
6 Division of Anatomic Pathology, University of Ancona, Ancona, Italy
Primary cutaneous T-cell lymphomas are a heterogeneous group of extranodal NH lymphomas primarily presenting in the skin without extracutaneos involvement at diagnosis. Treatment choices closely depend on clinic-pathologic entity and disease stage. Among available choices, oral bexarotene has shown efficacy and safety both in monotherapy and in association with other treatments, by virtue of its versatility and high synergism with alpha-interferon, photochemotherapy (PUVA), and chemotherapy. Moreover, when associated with a wise management of its side effects, bexarotene is well tolerated if used in long-term administration, and it is therefore a good candidate to maintenance treatment after different induction therapies. Recently, the Gruppo Italiano Linfomi Cutanei (GILC) has started some pilot studies, with the aim to investigate bexarotene potential in association with PUVA and single agent chemotherapy (as pegylated liposomal doxorubicin and gemcitabine), and as consolidation/maintenance treatment. The preliminary results of GILC pilot studies confirm the good tolerability and safety of low-intermediate dose bexarotene, and its potential synergism with PUVA and chemotherapy. In addition, its use in consolidation/maintenance has proven efficacy in improving overall response rate.